



Encenicline

Catalog No: tcsc0933

Available Sizes
Size: 5mg
Size: 10mg
Size: 50mg
Size: 100mg
Specifications
CAS No: 550999-75-2
Formula: C ₁₆ H ₁₇ CIN ₂ OS
Pathway: Neuronal Signaling;Membrane Transporter/Ion Channel
Target: nAChR;nAChR
Purity / Grade: >98%
Solubility: 10 mM in DMSO
Alternative Names: EVP-6124
Observed Molecular Weight: 320.84





Product Description

Encenicline (EVP-6124) is a novel partial agonist of $\alpha 7$ neuronal nicotinic acetylcholine receptors (**nAChRs**).

IC50 & Target: α7 nAChR^[1]

In Vitro: Encenicline (EVP-6124) displaces [3 H]-MLA (Methyllycaconitine) (K_i =9.98 nM, pIC $_{50}$ =7.65±0.06, n=3) and [125 I]- α -bungarotoxin (K_i =4.33 nM, pIC $_{50}$ =8.07±0.04, n=3). Encenicline (EVP-6124) is approximately 300 fold more potent than the natural agonist ACh (K_i =3 μ M), measured in binding assays using [3 H]-MLA. Encenicline inhibits the 5-HT $_3$ receptor by 51% at 10 nM, the lowest concentration tested. Evaluation of the human 5-HT $_{2B}$ receptor expressed in CHO cells demonstrates displacement of [3 H]-mesulergine (K_i =14 nM) and only antagonist activity in the rat gastric fundus assay at an IC $_{50}$ of 16 μ M. In binding and functional experiments, Encenicline shows selectivity for α 7 nAChRs and does not activate or inhibit heteromeric α 4β2 nAChRs $^{[1]}$.

In Vivo: Encenicline (EVP-6124) has good brain penetration and an adequate exposure time. Encenicline (EVP-6124) (0.3 mg/kg, p.o.) significantly restores memory function in scopolamine-treated rats (0.1 mg/kg, i.p.) in an object recognition task (ORT). Although donepezil at 0.1 mg/kg, p.o. or Encenicline at 0.03 mg/kg, p.o. did not improve memory in this task, co-administration of these sub-efficacious doses fully restored memory. In a natural forgetting test, an ORT with a 24 h retention time, Encenicline improved memory at 0.3 mg/kg, p.o. This improvement is blocked by the selective α 7 nAChR antagonist methyllycaconitine (0.3 mg/kg, i.p. or 10 μ g, i.c.v.). Encenicline (EVP-6124) is found to bind moderately to rat plasma proteins with a mean fu of 0.11 \pm 0.01 (mean \pm SD) or 11%. Over a range of 0.1-30 mg/kg, p.o., Encenicline (EVP-6124) demonstrates proportional dose escalation. T_{max} is at 4 h in plasma and 2 h brain, although the brain concentrations remained similar between 2 and 8 h. The B:P ratios are 1.7-5.1 between 1 and 8 h^[1]. Pharmacokinetic studies have shown that Encenicline (EVP-6124) (0.4 mg/kg, i.p.) reaches peak brain concentration 2 hr after administration and remains at effective concentrations for at least 4 hr. Encenicline (EVP-6124) is administered to WT mice at ZTO (0.4 mg/kg i.p single dose) and significantly increases the saturation index of NMDARs in slices obtained 4 hr later without causing prolonged wakefulness or enhanced locomotor activity [2].

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!